Benzinga
Published Nov 16, 2023 16:00
Updated Nov 16, 2023 17:10
Industry Comparison: Evaluating DexCom Against Competitors In Health Care Equipment & Supplies Industry
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating DexCom (NASDAQ:DXCM) against its key competitors in the Health Care Equipment & Supplies industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
DexCom Background Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
DexCom Inc | 112.21 | 17.18 | 12.83 | 5.53% | $0.29 | $0.62 | 26.69% |
Abbott Laboratories | 33.33 | 4.54 | 4.29 | 3.85% | $2.66 | $5.54 | -2.56% |
Stryker Corp | 42.08 | 6.02 | 5.47 | 3.92% | $1.2 | $3.16 | 9.6% |
Medtronic PLC | 27.31 | 1.92 | 3.13 | 1.54% | $2.02 | $5.07 | 4.49% |
Boston Scientific Corp | 65.67 | 4.18 | 5.70 | 2.72% | $0.98 | $2.43 | 11.26% |
Becton Dickinson & Co | 45.84 | 2.63 | 3.48 | 0.42% | $0.88 | $1.7 | 4.28% |
Edwards Lifesciences Corp | 28.64 | 6.10 | 7.04 | 5.91% | $0.46 | $1.13 | 12.27% |
IDEXX Laboratories Inc | 46.98 | 29.50 | 10.78 | 17.75% | $0.31 | $0.55 | 8.78% |
GE HealthCare Technologies Inc | 21.22 | 4.57 | 1.69 | 5.27% | $0.93 | $1.94 | 5.38% |
Zimmer Biomet Holdings Inc | 48.89 | 1.85 | 3.19 | 1.31% | $0.51 | $1.24 | 5.02% |
ResMed Inc | 24.74 | 5.27 | 5.13 | 5.24% | $0.34 | $0.6 | 16.0% |
Steris PLC | 36.87 | 3.25 | 3.89 | 1.87% | $0.34 | $0.59 | 11.82% |
Baxter International Inc | 76.76 | 2.21 | 1.17 | 36.69% | $0.28 | $1.12 | 2.74% |
Hologic Inc | 39.35 | 3.52 | 4.45 | 1.78% | $0.25 | $0.5 | -3.97% |
Insulet Corp | 100.84 | 19.94 | 7.85 | 8.94% | $0.08 | $0.29 | 26.97% |
Teleflex Inc | 24.75 | 2.30 | 3.38 | 3.22% | $0.23 | $0.42 | 8.68% |
Penumbra Inc | 217.03 | 7.97 | 8.91 | 0.85% | $0.04 | $0.18 | 26.8% |
Globus Medical Inc | 31.16 | 1.51 | 4.04 | 0.03% | $0.09 | $0.25 | 50.95% |
ShockWave Medical Inc | 26.67 | 10.49 | 9.72 | 5.74% | $0.05 | $0.16 | 41.64% |
Masimo Corp | 55.92 | 3.78 | 2.33 | 0.82% | $0.05 | $0.23 | -12.82% |
Envista Holdings Corp | 21.52 | 0.93 | 1.58 | 0.5% | $0.09 | $0.36 | 0.03% |
Average | 50.78 | 6.12 | 4.86 | 5.42% | $0.59 | $1.37 | 11.37% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } Upon analyzing DexCom, the following trends can be observed:
The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By evaluating DexCom against its top 4 peers in terms of the Debt-to-Equity ratio, the following observations arise:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.